

Program and Abstracts

International Conference of Nervous System Autoimmunity

Bangalore, India | January 27-30, 2012



Conference Organizer
ImmuneGlobe, LLC

Web: www.immuneglobeconference.com
Email: info@immuneglobeconference.com

Immune Globe, LLC is the organizer of this conference.

Mission

Immune Globe, LLC mission is to promote basic science discovery to disease therapy through organizing or coordinating scientific conferences, symposia and workshops.

Upcoming conference organized by Immune Globe:

“International Conference on Autoimmunity and Transplant Rejection”
Goa, India, September/October 2013. www.immuneglobeconference.com

Theme: Basic science discovery to autoimmune disease therapy/prevent transplant rejection.
Emphasis/Focus: Etiology, immunopathogenesis, pre-clinical studies and clinical trials
Announcement: Accepting nominations for co-chairs for the conference, symposium chairs, potential speakers, sponsors and suggestions.

© Copyright 2012 by Immune Globe, LLC

All Rights Reserved. Printed in India. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher.-
Immune Globe, LLC, 2951 Marina Bay Drive, Ste. 130-413, League City, Texas 77573-2785
USA.

Email: info@immuneglobeconference.com

Tel: 001-281-303-5507

Fax: 001-281-303-5507

Immune Globe NSA Conference Abstract 2012

Sponsors

SRM University – Chennai, India

LFB Biomedicaments – France

Myasthenia Gravis Foundation of Illinois – USA

Association Française contre les Myopathies – France

International Society of Neuroimmunology

Organizing Committee

Premkumar Christadoss – USA (Co-Chair)
Kantha D. Arunachalam – India (Co-Chair)
Yang Huan- China
Srini Kaveri – France
Sudheeran Kanooth- India
Erdem Tuzun – Turkey

Scientific Advisory Board

Sonia Berrih-Aknin – France
Premkumar Christadoss – USA
Marc DeBaets – Netherlands
Sara Fuchs – Israel
Reinhard Hohlfeld – Germany
Yang Huan – China
Srini Kaveri – France
Vijay Kuchroo – USA
Vanda Lennon-USA
Renato Mantegazza – Italy
Socrates Tzartos – Greece
Eroboghene Ubogu – USA
Robert Yu – USA

Program- At Taj Westend, Bangalore

January 27, 2012

4.00-7.00 PM- Registration

6.00-8.00 PM- Welcome reception and cocktail

January 28, 2012.

8.00-9.00 AM- Registration

8.45 AM- Organizer's welcoming remarks

I. Genes, Innate Immunity and the Role of Thymus

Chair- Sonia Berrih-Aknin

9.00-9.40 AM- Genes and lifestyle/environmental factors in MS (A101)

T. Olsson

Karolinska Institutet, Stockholm, Sweden.

9.45-10.25 AM- Innate immunity, thymus and autoimmunity (A102)

Paola Cavalcante, Pia Bernasconi, Fulvio Baggi and Renato Mantegazza.

Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.

10.30-11.10 AM- Defects of immunoregulation in Myasthenia Gravis (A103)

A. Gradolatto¹, D. Nazzari¹, M. Foti², F. Truffault¹ and S. Berrih-Aknin.¹

¹Unité Mixte de Recherche - CNRS UMR7215/INSERM U974/UPMC UM76/AIM - Thérapie des maladies du muscle strié, Paris, France and ²Genopolis Consortium, University of Milano-Bicocca, Department of Biotechnology and Bioscience.

11.15-11.30 AM- Coffee break

11.30-12.10 PM- Thymus pathology and the pathogenesis of myasthenia Gravis (A104)

A. Marx¹, B. Schalke², K. Wiebe³, W. Nix⁴, and P. STRÖBEL.¹

¹Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, D-68167 Mannheim, Germany. ²Neurological University Clinic, University of Regensburg, Regensburg, Germany, ³University of Münster, Münster, Germany and ⁴University of Mainz, Mainz, Germany.

12.15-12.35 PM- Thymoma plus Good-Syndrome and other multiple paraneoplastic syndromes (A105)

B. Schalke¹, S. Boy¹, R. Kollanur¹, R. Neu², S. Hofmann², J. Marienhagen³, F. Heinemann⁴, U. Bogdahn¹, P. Stroebel⁵ and A. Marx⁵.

¹Medical Centre, University of Regensburg Dep of Neurology, ²Dep of Thoracic Surgery, ³Dep Nuclear Medicine, Hospital Donaustauf, and ⁴Centre for Pneumology, University of Heidelberg/Mannheim, ⁵Dep of Pathology.

12.40-2.00 PM- Lunch

II. Immunopathology

Chair- Vanda Lennon

2.00-2.40 PM- NMO: An Autoimmune Channelopathy of Astrocytic Synapses (A106)

V.A. Lennon

Mayo Clinic, Rochester, USA.

2.45-3.25 PM- The biology of the human blood-nerve barrier: Implications for pathogenic leukocyte trafficking in immune-mediated polyneuropathies (A107)

E.E. Ubogu

Baylor College of Medicine, Houston, USA.

3.30-3.45 PM- Coffee break

3.45-4.25PM- The p.Arg63Trp polymorphism controls Vav1 functions, Foxp3 regulatory T cell development and susceptibility to central nervous system autoimmunity (A108)

C.Colacios, A. Casemayou, A. Dejean, B. Malissen, G.J. Fournié and Abdelhadi Saoudi.
Centre de Physiopathologie de Toulouse-Purpan, Inserm UMR1043 - CNRS UMR5282, Toulouse, France.

4.30- 5.10 PM- Autoimmunity at the neuromuscular junction (A109)

A. Gomez, M. Losen, P. Martinez-Martinez, P. Molenaar, R. Klooster, J. Plomp, J. Verschuuren and M. De Baets.

Maastricht University Hospital, Leiden University Medical centre. The Netherlands.

5.15-5.45 PM- Activation of complement is dispensable for myasthenia gravis caused by MuSK antibodies (A110)

K. Shigemoto, S. Mori, S. Kubo, S. Yamada and T. Miyazaki.

Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

January 29, 2012

III. Autoantibodies

Chair- Robert Yu

8.30- 9.10 AM- Autoimmune mechanisms of peripheral neuropathies: Role of anti-carbohydrate antibodies in Guillain-Barré syndrome (A111)

R.K. Yu

Institute of Molecular Medicine and Genetics and Institute of Neuroscience, Georgia Health Sciences University, Augusta, USA.

9.15- 9.55 AM- Autoantibodies, nerve repair, and new therapeutic targets in GBS (A112)

K. A. Sheikh

University of Texas Medical School at Houston, Houston, TX, USA.

10.00- 10.30 AM- Immunotherapy-responsive central nervous system diseases with antibodies to neuronal surface proteins (A113)

A. Vincent, S. Irani, P. Waters and B. Lang.

Neuroimmunology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

10.35- 10.55 AM- Myasthenic MuSK autoantibodies reduce tyrosine phosphorylation of AChR β -subunit and displace ACh receptor and rapsyn from the postsynaptic scaffold (A114)

N. Ghazanfari¹, RN. Cole¹, M. Morsch¹, SR. Reddel², and WD. Phillips¹

¹University of Sydney, Sydney, Australia; ²Concord Hospital, Sydney, Australia

11.00-11-15 AM- Coffee break

11.15-11.35 AM- Autoantibodies to neuronal antigens in patients with epilepsy (A115)

B. Lang¹, T. Brenner¹, Y. Hart², S. Howell³, G. Sills⁴, M. Brodie⁵, P. Waters¹ and A. Vincent.¹

¹University of Oxford, Oxford, UK; ²Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK; ³Royal Hallamshire Hospital, Sheffield, UK; ⁴University of Liverpool, Liverpool, UK; ⁵ and Western Infirmary, Glasgow, UK.

11.40-12.00 PM- Neuropsychiatric manifestations and associated autoantibodies in Systemic Lupus Erythematosus patients from Western India (A116)

V. Pradhan¹, A. Rajadhyaksha², M. Patwardhan¹, S. Dighe² and K. Ghosh.²

¹Department of Clinical & Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, 13th floor, KEM Hospital, Parel, Mumbai, India, and ²Department of Medicine, KEM Hospital, Parel, Mumbai, India.

IV. Cholinergic system and neuroinflammation

Chair- Talma Brenner

12.05-12.35 PM- Controlling neuroinflammation by the immune cholinergic system (A117)

T. Brenner, C. Sisicsic, H. Prinz-Hadad, and E. Nizri.
Hadassah-Hebrew-University Medical Center, Jerusalem, Israel.

12.40-1.00 PM- Cholinesterase inhibition potentiates postsynaptic acetylcholine receptor loss in a mouse model of anti-MuSK myasthenia gravis (A118)

M. Morsch¹, S. Reddel², N. Ghazanfari¹, W. Phillips.¹
¹University of Sydney, Sydney, Australia² and Concord Hospital, Sydney, Australia.

1.05-2.30 PM- Lunch

2.30-2.45 PM- Investigation and modulation of short-term and long-term neural plasticity and its implications in neurodegenerative disorders using various neurotoxins with *Drosophila melanogaster* as model organism (A119)

J. Gopalkrishna^{*1}, K. Govindaraju^{*1}, B. Kasargod^{*1}, and M. Agrahari^{1,2}. *Equal contributors to work. ¹PEST Institute of Technology, Bangalore, India and ²University of Calgary, Canada.

V. Novel Therapeutic Strategy

Chair- Mark De Baets

2.50-3.30 PM- The role of neural stem cells in brain regeneration (A120)

M. Gianvito
Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Hospital, Milan, Italy.

3.35- 4.05 PM- Complement C2 siRNA gene therapy for myasthenia gravis (A121)

R. Huda and P. Christadoss.
University of Texas Medical Branch, Galveston, USA.

4.10-4.50PM- Involvement of Treg cells and Aire in the pathogenesis of experimental myasthenia gravis (A122)

M.C. Souroujon^{1,2}, R. Aricha², S. Gertel², T. Feferman², K. Mizrachi², S. Berrih-Aknin³ and S. Fuchs²
¹Dept. of Natural Sciences, The Open University, Raanana, Israel. ²Dept. of Immunology, The Weizmann Institute of Science, Rehovot, Israel and ³INSERM, France

4.55-5.10 PM- Coffee Break

5.10-5.40 PM- DCs for the antigen specific therapy of experimental autoimmune myasthenia gravis (A123)

Yang H.¹, Zhang¹, Rauniyar¹V, and Christadoss P.²

¹Xiangya Hospital, Central South University, Changsha, Hunan, P.R.China and ²University of Texas Medical Branch, Galveston, USA.

5.45-6.15 PM- Silence of miRNA 155 negatively regulates the B cell response to Torpedo AChR (A124)

Y.Z. Wang, F.F. Tian, M. Yan, J.M. Zhang, Q. Liu, H. Yang, W.B. Zhou, B. Xiao, J.Li¹.
Central South University, Changsha, P. R. China.

6.45-11.30 PM- Farewell Dinner and Entertainment

January 30, 2012

VI. Therapy

Chair- Srini Kaveri

8.30- 9.15 AM- Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) (A125)

G I. Wolfe¹, G. R. Cutter², G. Minisman², I. Aban², A. Jaretzki III³, Robin Conwit, MD, H. J. Kaminski⁴, ¹University of Texas Southwestern Medical Center; ²University of Alabama at Birmingham; and ³Columbia University, NIH/NINDS; ⁴George Washington University.

9.20- 10.00 AM- Mechanisms of action of intravenous immunoglobulins in neuroimmunological conditions (A126)

S. Kaveri

INSERM , Centre de Recherche des Cordeliers, Paris, France.

10.05-10.35- Rituximab, a therapeutic regimen for myasthenia gravis and Neuro-Sjögren's syndrome (A127)

W. Baek.

South California Permanente Medical Group, Ontario, USA

10.40- 11.00- Coffee Break

11.00-1.00 PM- Translational Research Network meeting and luncheon

12.00-1.30 PM- Farewell Lunch

2.00- 5.00 PM- Visit Temples and shopping centers in Bangalore

ABSTRACTS

To view the remaining information in this 36 page document, please contact info@immuneglobeconference.com for more information.